Sapient Capital’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.74B Buy
1,447,540
+3,185
+0.2% +$3.25M 22.72% 1
2026
Q1
$1.33B Sell
1,444,355
-54,261
-4% -$55M 20.02% 1
2025
Q4
$1.62B Buy
1,498,616
+20,737
+1% +$19.8M 22.72% 1
2025
Q3
$1.07B Buy
1,477,879
+259,392
+21% +$193M 16.53% 1
2025
Q2
$950M Buy
1,218,487
+9,903
+0.8% +$7.7M 17.01% 1
2025
Q1
$998M Buy
1,208,584
+25,936
+2% +$21.6M 19.69% 1
2024
Q4
$913M Sell
1,182,648
-1,829
-0.2% -$1.51M 17.43% 1
2024
Q3
$1.05B Buy
1,184,477
+247
+0% +$222K 21.07% 1
2024
Q2
$1.07B Buy
1,184,230
+6,908
+0.6% +$5.53M 22.32% 1
2024
Q1
$916M Buy
1,177,322
+7,111
+0.6% +$5.06M 20.29% 1
2023
Q4
$682M Buy
+1,170,211
New +$683M 17.6% 1

Other funds holding LLY

Sapient Capital's LLY Position: Q2 2026 in Review

Sapient Capital increased its Eli Lilly (LLY) stake by 0.22% in Q2 2026, buying an estimated $3.25M and bringing the position to 1,447,540 shares worth $1.74B. The position accounts for 22.72% of the portfolio, ranked #1.

Sapient Capital first reported a position in LLY in Q4 2023 and has held it in 11 quarters since. 1,558 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Sapient Capital held 1,447,540 shares of Eli Lilly worth $1.74B as of Q2 2026.
  • Sapient Capital bought 3,185 Eli Lilly shares in Q2 2026, an estimated $3.25M.
  • Eli Lilly made up 22.72% of Sapient Capital's portfolio in Q2 2026, its #1 holding.
  • Sapient Capital first reported a position in Eli Lilly in Q4 2023 and has held it in 11 quarters since.
  • 1,558 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Sapient Capital's 13F filing for Q2 2026, filed 9 Jul 2026.